Trial · NCT03677141
Results by group230
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 230
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC) | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 72.5 | 95% Confidence Interval 56.11 to 85.40 | Percentage of participants | |
| Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 77.3 | 95% Confidence Interval 54.63 to 92.18 | Percentage of participants | |
| CR Rate at PRA Based on CT Only as Determined by the Investigator (Phase II) | Group C: Phase II Mosunetuzumab + CHOP | 50.0 | 95% Confidence Interval 33.80 to 66.20 | Percentage of participants | |
| CR Rate at PRA Based on CT Only as Determined by the Investigator (Phase II) | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 47.5 | 95% Confidence Interval 31.51 to 63.87 | Percentage of participants | |
| CR Rate at PRA Based on CT Only as Determined by the Investigator (Phase II) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 31.8 | 95% Confidence Interval 13.86 to 54.87 | Percentage of participants | |
| Overall Response Rate (ORR) at PRA Based on PET-CT as Determined by the Investigator (Phase II) | Group C: Phase II Mosunetuzumab + CHOP | 87.5 | 95% Confidence Interval 73.20 to 95.81 | Percentage of participants | |
| Overall Response Rate (ORR) at PRA Based on PET-CT as Determined by the Investigator (Phase II) | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 80.0 | 95% Confidence Interval 64.35 to 90.95 | Percentage of participants | |
| Overall Response Rate (ORR) at PRA Based on PET-CT as Determined by the Investigator (Phase II) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 77.3 | 95% Confidence Interval 54.63 to 92.18 | Percentage of participants | |
| ORR at PRA Based on CT Only as Determined by the Investigator (Phase II) | Group C: Phase II Mosunetuzumab + CHOP | 85.0 | 95% Confidence Interval 70.16 to 94.29 | Percentage of participants | |
| ORR at PRA Based on CT Only as Determined by the Investigator (Phase II) | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 72.5 | 95% Confidence Interval 56.11 to 85.40 | Percentage of participants | |
| ORR at PRA Based on CT Only as Determined by the Investigator (Phase II) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 81.8 | 95% Confidence Interval 59.72 to 94.81 | Percentage of participants | |
| Best ORR Based on PET-CT and/or CT Scan as Determined by the Investigator (Phase II) | Group C: Phase II Mosunetuzumab + CHOP | 95.0 | 95% Confidence Interval 83.08 to 99.39 | Percentage of responders | |
| Best ORR Based on PET-CT and/or CT Scan as Determined by the Investigator (Phase II) | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | 85.0 | 95% Confidence Interval 70.16 to 94.29 | Percentage of responders | |
| Best ORR Based on PET-CT and/or CT Scan as Determined by the Investigator (Phase II) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | 95.5 | 95% Confidence Interval 77.16 to 99.88 | Percentage of responders | |
| Duration of Response (DOR) as Determined by the Investigator (Phase II) | Group C: Phase II Mosunetuzumab + CHOP | NA | Full Range 0 to 28 | Months | |
| Duration of Response (DOR) as Determined by the Investigator (Phase II) | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | NA | Full Range 0 to 28 | Months | |
| Duration of Response (DOR) as Determined by the Investigator (Phase II) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | NA | Full Range 1 to 27 | Months | |
| Progression-free Survival (PFS) as Determined by the Investigator (Phase II) | Group C: Phase II Mosunetuzumab + CHOP | NA | Full Range 0 to 31 | Months | |
| Progression-free Survival (PFS) as Determined by the Investigator (Phase II) | Arm 1: Phase II Mosunetuzumab + CHP-Pola (Randomized) | NA | Full Range 0 to 30 | Months | |
| Progression-free Survival (PFS) as Determined by the Investigator (Phase II) | Arm 2: Phase II Rituximab + CHP-Pola (Randomized) | NA | Full Range 3 to 30 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03677141/results